An Open Study of the Safety, Tolerability and Immunogenicity of the Drug "Gam-COVID-Vac" Vaccine Against COVID-19 - Full Text View - ClinicalTrials.gov
from Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
Component 1 consists of a recombinant adenovirus vector based on the human adenovirus type 26, containing the SARS-CoV-2 S protein gene
Component 2 consists of a vector based on the human adenovirus type 5, containing the SARS-CoV-2 S protein gene.
Day 1 rAd26 Component
Day 21 rAd5 Component
Intervention Model Description: An open, prospective, two-stage, non-randomized,
first-phase study involving healthy volunteers
Actual Study Start Date : June 17, 2020
Estimated Primary Completion Date : August 5, 2020
Estimated Study Completion Date : August 15, 2020